Content deleted Content added
m Disambiguated: colon → Large intestine |
→Lutathera: see also: PRRT |
||
Line 33:
===Lutathera===
{{see also|Peptide receptor radionuclide therapy}}
The company's lead product is LUTATHERA, a Lutetium Lu 177 dotatate <ref>[https://hemonc.org/wiki/Lutetium_Lu_177_dotatate_(Lutathera)</ref> labeled [[DOTA-TATE|somatostatin analogue peptide]], a theragnostic cancer product being developed to treat certain gastro-entero [[pancreatic]] [[neuroendocrine tumors]] ([[GEP-NET]]s). It selectively targets over-expressed somatostatin receptors while also giving off gamma emissions to allow physicians to visualize where in the body both the drug and the tumor are.
It was approved by the FDA in January 2018 for GEP-NET.<ref>[https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/%7B5e89833e-97c3-4a91-a2c8-88231a517b78%7D/fda-approves-lutathera-for-gastroenteropancreatic-neuroendocrine-tumors ''FDA approves Lutathera for gastroenteropancreatic neuroendocrine tumors'' Jan 2018]</ref>
| |||